Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for methylprednisolone
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylprednisolone or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on methylprednisolone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
A controlled trial of methylprednisolone in the emergency treatment of acute asthma. 3510384 1986 02 06 1986 02 06 2013 11 21 0028-4793 314 3 1986 Jan 16 The New England journal of medicine N. Engl. J. Med. A controlled trial of methylprednisolone in the emergency treatment of acute asthma. 150-2 Ninety-seven acutely ill patients with bronchial asthma were enrolled in a double-blind, placebo-controlled, randomized trial of intravenous methylprednisolone (125 mg), given on presentation (...) in the emergency room in addition to standard emergency treatments for asthma. Subjective and spirometric indexes of the severity of the asthma were similar on entry into the study in all patients, but only 9 of 48 patients (19 percent) treated with methylprednisolone required hospital admission, as compared with 23 of 49 patients (47 percent) in the control group (P less than 0.003). Our results suggest that prompt use of glucocorticoids in the emergency treatment of severe asthma can prevent significant
Efficacy of methylprednisolone in acute spinal cord injury. 6361287 1984 02 14 1984 02 14 2016 10 17 0098-7484 251 1 1984 Jan 06 JAMA JAMA Efficacy of methylprednisolone in acute spinal cord injury. 45-52 A multicenter double-blind randomized trial was conducted to examine the efficacy of a high dose of methylprednisolone (1,000-mg bolus and daily thereafter for ten days) compared with a standard dose (100-mg bolus and daily thereafter for ten days) in 330 patients with acute spinal cord injury (...) Methylprednisolone AIM IM Acute Disease Adolescent Adult Aged Clinical Trials as Topic Double-Blind Method Female Follow-Up Studies Humans Male Methylprednisolone administration & dosage adverse effects therapeutic use Middle Aged Random Allocation Risk Spinal Cord Injuries drug therapy mortality surgery Time Factors Wound Infection epidemiology 1984 1 6 2001 3 28 10 1 1984 1 6 0 0 ppublish 6361287
Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. 6366560 1984 04 26 1984 04 26 2013 11 21 0028-4793 310 15 1984 Apr 12 The New England journal of medicine N. Engl. J. Med. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. 946-50 Sixty-seven adults with idiopathic membranous nephropathy and the nephrotic syndrome were randomly assigned to symptomatic treatment only or to a six-month course (...) of methylprednisolone alternated with chlorambucil every other month. Patients were followed for one to seven years. At the end of follow-up (mean of 31.4 +/- 18.2 months for the treated group and 37.0 +/- 22.0 for the control group) 23 of 32 treated patients were in complete or partial remission, as compared with 9 of 30 control patients (P = 0.001). Twelve of the treated patients were in complete remission, as compared with only two of the controls. In the treated group there were no changes in renal function
A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. 6124671 1982 09 10 1982 09 10 2015 06 16 0140-6736 2 8292 1982 Jul 31 Lancet (London, England) Lancet A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. 237-40 To confirm the findings of uncontrolled trials that methylprednisolone pulse therapy (MPPT) is a safe treatment for active rheumatoid disease, a double-blind trial was conducted (...) in which 20 patients with active rheumatoid disease were randomly allocated to receive an infusion of either 1 g methylprednisolone or placebo. Methylprednisolone produced significant improvement in all clinical variables measured, a benefit which was sustained for at least 6 weeks. The placebo produced only transient improvement in some of the clinical variables measured. when the 10 placebo groups patients were later given an infusion of 1 g methylprednisolone, they too showed significant clinical
Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Controlled clinical trial of meth... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1980 ) Volume: 92 , Issue: 6 , Pages: 753-758 PubMed: Available from or Find this paper at: Abstract To evaluate the role of corticosteroids as treatment for acute exacerbations (...) of chronic obstructive pulmonary disease, we conducted a double-blind, randomized, placebo-controlled trial in 44 consecutive patients with chronic bronchitis and severe airflow obstruction. All were hospitalized with acute respiratory insufficiency from acute bronchitis. Patients with asthma, atopy, or pneumonia were excluded. Treatment consisted of intravenous aminophylline, inhaled isoproterenol, antibiotics, and either methylprednisolone, 0.5 mg/kg of body weight, or placebo every 6 h intravenously for 72 h. Bedside spirometry